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Aim: To evaluate health-related quality of life (health utility) scores in patients with diabetes receiving insulin degludec (IDeg) or insulin
glargine (IGlar).
Methods: Patient-level data from six, randomized, controlled, open-label, multicentre, conﬁrmatory, treat-to-target trials of 26- or 52 weeks’
duration were pooled in this analysis. The Short Form 36 (SF-36) version-2 health questionnaire was completed by patients at baseline and
end-of-trial. SF-36 scores for 4001 individual patients were then mapped onto the EuroQol-5D health utility scale, which has a range from
−0.59 (a state worse than death) to 1.00 (perfect health).
Results: IDeg treatment exhibited a signiﬁcant improvement in health status of 0.005 (CI: 0.0006; 0.009) points compared with IGlar
(p< 0.024). Gender, region, trial and age also had a signiﬁcant inﬂuence on estimated utility scores as did baseline utility scores, p< 0.05. Prior
to the removal of interaction variables a difference of 0.008 points was observed, p< 0.045. Previous insulin treatment did not have an impact
on the ﬁnal outcome.
Conclusion: This study shows that IDeg is associated with a modest, but statistically signiﬁcant, improvement in health utility compared with
IGlar in patients with diabetes.
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Introduction
Diabetes places a significant burden upon health-related quality
of life (HRQoL), with patients experiencing a reduction in
both total and healthy life years as a result of disability and
related co-morbidities [1]. Additional challenges arise during
the management of diabetes, where the fear of hypoglycaemia,
fear of injections and complex treatment regimens are major
concerns among patients [2–4]. These factors have a negative
impact on HRQoL, and incur economic costs to the individual
and the healthcare system [5–8]. Increasingly, the health
economic value attached to health status is used to inform
the decisions of healthcare payers when assessing the cost-
effectiveness of new treatments [9]. For the purpose of health
economics, HRQoL may be expressed as a single preference
value, health utility, where zero is equivalent to death and one
represents perfect health. Typical values for diabetes patients
without complications range between 0.9 (type 1) and 0.85
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(type 2), and are lower in those with complications [10,11].
Quality-adjusted life years (QALYs), a widely used measure of
health improvement, are formed by combining health utility
scores with a relevant time horizon [12].
Insulin degludec (IDeg) is a new-generation ultra-long
acting basal insulin that forms soluble multi-hexamers upon
subcutaneous injection, achieving a stable glucose-lowering
effect lasting beyond 42 hours [13,14]. The safety and efficacy
of IDeg has been compared with insulin glargine (IGlar) in
clinical trials, where IDeg has shown lower rates of day-to-day
and hour-to-hour blood-glucose variability [15], and a reduced
risk of hypoglycaemia at equivalent levels of glycaemic control
[16–20]. Furthermore, IDeg has previously been shown to
improve QoL compared with IGlar in both type 1 diabetes mel-
litus (T1D) and type 2 diabetes mellitus (T2D) [17,19,21,22].
The aim of this meta-analysis was to evaluate health utility
scores in patients with diabetes receiving IDeg or IGlar.
Methods
Study Population and Clinical Endpoints
The IDeg clinical trial programme used similar methodologies
across trials to allow data to be grouped for meta-analyses.
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Table 1. Baseline characteristics for all patients in each of the six trials included in the meta-analysis.
Study id
Short trial
name
Prestudy
treatment
numbers Age (years)
Diabetes duration
(years) BMI (kg/m2) HbA1c (%) FPG (mg/dl)
3582 [17] BEGIN™ T2 BB 992 58.9 ± 9.3 13.5 ± 7.3 32.2 ± 4.6 8.3 ± 0.8 166 ± 56
3583 [18] BEGIN™ T1 BB LONG 629 43.0 ± 13.6 18.9 ± 12.0 26.3 ± 3.8 7.7 ± 1.0 168 ± 74
3579 [19] BEGIN™ Once Long 1030 59.1 ± 9.8 9.2 ± 6.2 31.1 ± 4.7 8.2 ± 0.8 175 ± 47
3586 [23] BEGIN™ ONCE ASIA 435 58.6 ± 9.9 11.6 ± 6.5 25.0 ± 3.6 8.5 ± 0.8 153 ± 36
3668 [24] IDeg Flexible versus IDeg
Fixed and IGlar in T2D
458 56.4 ± 9.6 10.6 ± 6.7 29.6 ± 4.7 8.4 ± 0.9 160 ± 49
3672 [25] BEGIN™ LOW
VOLUME
457 57.5 ± 9.2 8.2 ± 6.2 32.4 ± 5.4 8.3 ± 0.9 173 ± 49
Total — 4001 56.0 ± 11.7 12.1 ± 8.4 30.0 ± 5.3 8.2 ± 0.9 166.9 ± 54.1
Data are mean values ± standard deviation unless otherwise stated.
BB, basal–bolus; BMI, body mass index; FPG, fasting plasma glucose; IDeg, insulin degludec; IGlar, insulin glargine; n/a, data not available; T2D, type 2
diabetes mellitus.
All phase 3a clinical trials where IDeg once daily (OD) was
compared with IGlar OD, and where QoL was evaluated, were
included in this analysis (Table 1) [17,18,23–25]. Patient-level
data (n = 4001) from six, randomized, controlled, open-label,
multicentre, confirmatory, treat-to-target trials of 26- or 52
weeks’ duration were pooled in this analysis. These included one
trial in T1D using basal−bolus (BB) therapy (id #3583 [18]),
one in T2D using BB (id #3582 [17]), and four in T2D using
basal insulin supported oral therapy (id #3579, 3586, 3668,
3672 [19,23–25]). Patients received either IDeg or IGlar OD in
each of these trials. Basal insulin doses were administered using
either the FlexTouch® (Novo Nordisk, Bagsvaerd, Denmark) or
SoloStar® (sanofi-aventis, Paris, France) pen injectors for IDeg
and IGlar, respectively – vials/syringes were not used in any of
the studies. Inclusion criteria required patients to be ≥18 years
of age, with a duration of diabetes ≥6 months, glycated
haemoglobin (HbA1c) ≤11% and a body mass index (BMI)
≤45 kg/m2. In study 3668 [24], there were three treatment
arms: IDeg fixed dosing, IGlar fixed dosing and IDeg flexible
dosing. In the fixed-dosing arms, as with all other trials, the
basal insulin dose was administered at the same time every day.
In the IDeg flexible dosing arm, insulin doses were administered
at alternating 8- and 40-h intervals. To prevent differences in
the timing of insulin dose administration from confounding
the results, the IDeg flexible dosing arm in study 3668 was
excluded from this meta-analysis. A seventh phase 3a study
(id #3770 [26]) was not included in this meta-analysis because
QoL data were not recorded. This analysis included both
insulin-experienced and insulin-naı¨ve patients. Individuals
were excluded from the trials if they had recurrent severe
hypoglycaemia (≥1 event, requiring third-party assistance, in
the preceding 12 months). Basal insulin doses were titrated to a
target fasting plasma glucose (FPG) concentration of 90 mg/dl
(5 mmol/l). Glycaemic control was evaluated via measurement
of HbA1c and FPG concentrations. Safety analysis included
the recording of confirmed hypoglycaemic events. These
were defined as blood glucose concentrations <56 mg/dl
(3.1 mmol/l) or requiring third-party assistance, and were
considered as nocturnal if onset occurred between 00:01 and
05:59 (inclusive) hours. Owing to the global nature of the
phase 3a programme, health questionnaires were translated and
validated in the appropriate languages. Detailed descriptions
of the study methodology are available in previously published
literature [17–19].
In all trials, IDeg achieved non-inferiority of glycaemic
control, as measured by change in HbA1c from baseline
compared with IGlar – as would be expected in treat-to-
target studies. FPG and nocturnal hypoglycaemic events were
numerically or significantly reduced, and overall confirmed
hypoglycaemic events were equal to or fewer for IDeg compared
with IGlar. Detailed results of individual trials have been
published [17–19].
Health Utility (HRQoL) Assessment
The Short Form 36 (SF-36) version-2 health questionnaire
was completed by patients at baseline and end-of-trial. The
SF-36 comprises 36 questions, which yield scores for eight
scales and which are summarized into two health measures
concerning physical and mental health [27]. As with health
utility, an increase in SF-36 scores represents an improvement
in health; however, SF-36 scores are not based on individual
preferences. In this analysis, generic HRQoL scores from the
SF-36 instrument were converted into EuroQol-5D, (EQ-5D)
health utility scores [28], by use of a method adopted from
Rowen et al. [29] (figure 1). To generate the EQ-5D, each SF-36
scale is rescaled onto a −0.59 (worst health) to 1 (best health)
scale before applying the mapping algorithm. Rowen et al.
examined a number of different models for mapping SF-36
scores on to EQ-5D, and compared the performance of the
various specifications via their ability to accurately predict EQ-
5D scores from SF-36 scores using a ‘real-world’ dataset. Their
preferred model (based on observed vs. predicted precision)
is a random effect, generalized least squares model, where
SF-36 domain scores, squared domain scores and interactions
between domain scores are included [29]. It was not appropriate
to use an ordinal least squares model, due to a lack of normality
across the disease severity range and interaction effects between
dimensions. The preferred prediction model had the highest
predictive value in less severe health states compared with
more severe health states. Health status scores in the present,
IDeg, clinical trials match the range where predictive value is
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Limitations of physical 
activity including walking 
and dressing 
Physical functioning (PF)
Mapping
algorithm:
0.559*PF –0.146*RP +0.175*BP
+0.407*GH +0.017*VT +0.293*SF
+0.067*RE +0.483*MH –0.227*PF2
+0.001*RP2 –0.330*BP2
–0.032*GH2 –0.012*VT2 –0.163*SF2
+0.034*RE2 –0.242*MH2
+0.022*PF*RP –0.032*PF*BP
+0.073*PF*GH –0.123*PF*VT
–0.023*PF*SF +0.047*PF*RE
–0.014*PF*MH +0.019*RP*BP
+0.068*RP*GH +0.050*RP*VT
+0.067*RP*SF –0.012*RP*RE
+0.022*RP*MH –0.217*BP*GH
–0.002*BP*VT +0.055*BP*SF
–0.038*BP*RE –0.131*BP*MH
–0.066*GH*VT –0.157*GH*SF
–0.033*GH*RE –0.084*GH*MH
+0.143*VT*SF –0.020*VT*RE
+0.023*VT*MH –0.023*SF*RE
–0.065*SF*MH –0.048*RE*MH
+0.256
Limitations of work
accomplishment,
type, difficulty
Amount of pain and 
interference with work
Role-physical (RF)
Bodily pain (BP)
Rating of health, comparison 
with others, and expectation 
for the future
General health (GH)
Energy and tiredness 
ratings Vitality (VT)
EQ-5D
score
Limitations to time and type 
of social activities
Reduced work time, 
accomplishment, and
quality
Social functioning (SF)
Role-emotional (RE)
Anxiety/serenity, depressed 
mood/happiness Mental health (MH)
Figure 1. Short Form 36 (SF-36) to EuroQol-5D (EQ-5D) conversion algorithm: integrated with outline of SF-36 questionnaire. To generate the EQ-5D,
each SF-36 scale is rescaled onto a zero (worst health) to one (best health) scale before applying the mapping algorithm.
greatest, therefore this model was deemed appropriate. The
National Institute for Health and Clinical Excellence (NICE)
recommends the use of EQ-5D when measuring health utility.
When EQ-5D has not been directly assessed, NICE favours the
adoption of mapping scores to EQ-5D over the use of alternate
measures, such as SF-6D [30]. Patient-level SF-36 data from
the individual trials were then mapped to EQ-5D. This enabled
the direct estimation of a utility value for individuals (EQ-5D
individual mapping), and permitted conditioning of relevant
patient characteristics on an individual subject-level detail in
the final statistical model.
Two alternative utility models were applied to test the
sensitivity of our approach, but were also relevant in assessing
the robustness of the parameter estimate derived from the
primary mapping model. The SF-6D is a widely used direct
index (e.g. not mapped via EQ-5D) which as with the EQ-
5D is also based on respondent preferences [31]. The index
comprises six dimensions and can yield 18 000 unique health
states/utility values. Lastly, an algorithm mapping mean SF-36
scores to the EQ-5D (EQ-5D aggregate mapping) was also
tested as alternative to the primary model [32].
Statistical Analysis
Data from individual trials were pooled using a fixed-effects
model. SF-36 scores for 4001 individual patients were mapped
onto EQ-5D and a generalized linear regression was applied
subsequently, using SAS v9.1.3 (SAS Institute, Cary, North
Carolina, USA), to estimate the treatment effect of IDeg and
IGlar in terms of utility. EQ-5D scores can exhibit a ceiling
effect when a large proportion of subjects describe perfect health
(=1). However, ceiling effects did not seem to be an issue in this
study population. Although a large proportion of patients has
scores at the high end (the percentage of patients having values
>0.95 was 63.5 and 65.9% at baseline, and 58.0 and 61.1% at
follow-up, for IDeg and IGlar, respectively) no patients reached
the ceiling at baseline or follow-up in either treatment group
(figure 2). The absence of patients reaching the ceiling is a
result of the EQ-5D values being modelled from the SF-36
scale. Furthermore, none of the patients reached the ceiling on
the SF-36 scale; therefore, it is unlikely that this would be the
case for the EQ-5D predicted values. It should, however, be
noted that a fairly large proportion are at the higher end of the
scoring range as would be expected in patients with diabetes
who do not have major health complications [33,34]. We
conducted an analysis of covariance, using end-of-trial utilities
as endpoint and baseline utility, treatment (IDeg vs. IGlar),
trial, region, gender, age and previous insulin treatment as
independent variables. Also, the initial model included a vector
of interaction variables of treatment by trial. These variables
were used to examine whether treatment results differed by trial.
As a sensitivity analysis, a linear model with interaction
variables of key clinical markers was specified to test for
statistical prediction power of the utility difference. Age is
normally a pivotal driver of utility; therefore, several different
specifications of age (log, exponential or quadratic) were
assessed as alternatives to linear age in the model.
SF-6D utility scores were calculated using the scoring
algorithms developed by Brazier et al. [31]. The change in
score was analysed using the same model as was applied for
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Figure 2. EuroQol-5D (EQ-5D) scores − empirical distribution function.
Table 2. Utility scores at baseline and follow-up for the EQ-5D individual mapping algorithm.
IDeg IGlar
Study id Baseline End-of-trial Baseline End-of-trial
3582 [17] 0.8843 ± 0.0931 0.8837 ± 0.0977 0.8858 ± 0.0948 0.8784 ± 0.0933
3583 [18] 0.9436 ± 0.0636 0.9430 ± 0.0599 0.9414 ± 0.0607 0.9342 ± 0.0711
3579 [19] 0.8958 ± 0.0867 0.9009 ± 0.0894 0.8951 ± 0.0912 0.8933 ± 0.0945
3586 [23] 0.9208 ± 0.0575 0.9286 ± 0.0618 0.9211 ± 0.0632 0.9273 ± 0.0566
3668 [24] 0.8958 ± 0.0797 0.9030 ± 0.779 0.8921 ± 0.0810 0.8972 ± 0.0912
3672 [25] 0.8957 ± 0.0887 0.9080 ± 0.0810 0.8889 ± 0.0858 0.8963 ± 0.0912
Values are mean ± standard deviation.
IDeg, insulin degludec; IGlar, insulin glargine.
EQ-5D. Finally, we derived EQ-5D scores through aggregate
mapping, by multiplying the raw non-normalized SF-36 scores
onto the parameter estimates provided in Ara et al. [32].
Results
Baseline Characteristics
The study population consisted of 4001 patients across six trials.
For the combined study population, the mean (±s.d.) age was
56.0 ± 11.7 years, duration of diabetes 12.1 ± 8.4 years, HbA1c
of 8.2 ± 0.9 mmol/mol, FPG 166.9 ± 54.1 mg/dl and BMI of
30.0 ± 5.3 kg/m2. Baseline values for the individual trials are
shown in Table 1. EQ-5D individual mapping scores at baseline
and follow-up are shown in Table 2.
Health Utility (EQ-5D)
In the sensitivity analysis, none of the alternative age
specifications markedly improved the model’s goodness-of-
fit (assessed by the Akaike Information Criterion (AIC) score,
[35]). Consequently, linear age was retained in the final model.
Testing for interaction variables did not yield a significant effect,
therefore the final model proceeds with the assumption that
there is no difference in effect between the treatment settings.
Cumulative treatment scores for the predicted EQ-5D are
shown in figure 2. IDeg treatment exhibited a significant
improvement in health status of 0.005 (CI: 0.0006; 0.009) points
compared with IGlar (p< 0.024) (Table 3). Gender, region,
trial and age also had a significant influence on estimated utility
scores as did baseline utility scores, p< 0.05 (Table 3). Prior to
the removal of interaction variables a difference of 0.008 points
was observed, p< 0.045 (Table 3). Previous insulin treatment
(Yes/No) did not have an impact on the final outcome (Table 3).
The results of the alternative algorithms generally agreed with
the findings of the primary EQ-5D mapping approach. Using
the SF-6D and EQ-5D aggregate mapping, the improvement
in health utility was 0.005 and 0.012, respectively. Although
statistical analysis comparing the aggregate scores was not
possible, the similarity between the three sets of results supports
the validity of the mapping algorithm in this study (Table 4). A
breakdown of the scores by treatment group for each algorithm
is shown in Table 4.
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Table 3. Overview of parameter estimates included in QALY regression analysis before and after backward elimination of candidate explanatory variables.
Variable Parameter Estimate (s.e.) before reduction p value Estimate (s.e.) in final model p value
Intercept — 0.313 (0.016) — 0.315 (0.016) —
Treatment — — 0.045 — 0.024
IDeg 0.008 (0.006) — 0.005 (0.002) —
IGlar 0 — 0 —
Gender — — 0.003 — 0.003
Female −0.006 (0.002) — −0.006 (0.002) —
Male 0 — 0 —
Region — — 0.016 — 0.017
Asia −0.024 (0.010) — −0.023 (0.010) —
Europe −0.015 (0.009) — −0.015 (0.009) —
Japan −0.024 (0.012) — −0.024 (0.012) —
North America −0.021 (0.009) — −0.021 (0.009) —
South Africa −0.014 (0.010) — −0.013 (0.010) —
South America 0 — 0 —
Insulin naı¨ve — — 0.329 — —
No −0.006 (0.006) — — —
Yes 0 — — —
Trial — — 0.006 — <0.0001
T2D BOT (3579) −0.007 (0.006) — −0.007 (0.003) —
T2D BB (3582) −0.009 (0.008) — −0.015 (0.003) —
T1D BB (3583) 0.001 (0.009) — −0.005 (0.004) —
T2D BOT Asia (3586) 0.014 (0.009) — 0.010 (0.008) —
T2D BOT Flex (3668) 0.002 (0.007) — −0.004 (0.005) —
T2D BOT U200 (3672) 0 — 0 —
Treatment by trial interaction — — 0.875 — —
IDeg × T2D BOT −0.002 (0.007) — — —
IDeg × T2D BB −0.001 (0.007) — — —
IDeg × T1D BB −0.001 (0.008) — — —
IDeg × T2D BOT Asia −0.006 (0.008) — — —
IDeg × T2D BOT Flex −0.009 (0.008) — — —
IDeg × T2D BOT U200 0 — — —
IGlar × T2D BOT 0 — — —
IGlar × T2D BB 0 — — —
IGlar × T1D BB 0 — — —
IGlar × T2D BOT Asia 0 — — —
IGlar × T2D BOT Flex 0 — — —
IGlar × T2D BOT U200 0 — — —
Age — −0.0005 (0.0001) <0.0001 −0.0005 (0.0001) <0.0001
Baseline utility — 0.712 (0.012) <0.0001 0.712 (0.012) <0.0001
p values are based on type III sums of squares test.
BB, basal–bolus; BOT, basal supported oral therapy; IDeg, insulin degludec; IGlar, insulin glargine; QALY, quality-adjusted life years; s.e., standard error;
T1D, type 1 diabetes mellitus; T2D, type 2 diabetes mellitus.
Conclusions
This study shows that IDeg is associated with a modest, but
statistically significant, improvement in health utility compared
with IGlar in patients with diabetes.
These results concur with those of recently published trials,
where IDeg has shown improvements in HRQoL compared
with IGlar [17,19,21,22], and go a step further by translating
this into health utility scores. The clinical trials included in
our meta-analysis are some of the first involving an injectable
insulin to measure HRQoL, and advance the use of patient-
reported outcomes (PRO) in evaluating the value of therapeutic
innovations in patients with diabetes.
It has been suggested that the reduced rate of hypoglycaemia
observed with basal insulin analogues versus human insulins
may be linked to improvements in HRQoL [21,22,36,37].
Conversely, a Cochrane review of studies involving basal insulin
analogues confirmed a reduction in the rate of hypoglycaemic
events compared with neutral protamine Hagedorn insulin,
but did not show a benefit to QoL as these trials had
not incorporated PRO assessments [38]. This highlights
the importance of considering HRQoL when designing and
implementing studies assessing the clinical value of novel
insulin preparations. As previously stated, hypoglycaemia
and fear of hypoglycaemia, are both major contributors
to reduced HRQoL in patients with diabetes; therefore,
it is possible that the improvement in health utility for
IDeg is due to a reduced rate of nocturnal hypoglycaemia.
However, other factors not recorded in the clinical trials
may have contributed to the documented difference. Although
non-severe hypoglycaemic episodes (NSHEs) have a negative
568 Freemantle et al. Volume 15 No. 6 June 2013
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Table 4. Sensitivity analysis for the EQ-5D individual mapping, EQ-5D
aggregate mapping and SF-6D algorithms.
QALYs
QALY gain
calculation
Treatment
regimen
EQ-5D individual
mapping
EQ-5D aggregate
mapping SF-6D
Separate T1D BB 0.007 0.007 0.005
T2D BOT 0.004 0.015 0.005
T2D BB 0.006 0.014 0.002
Aggregate ALL 0.005* 0.012 0.005
BB, basal–bolus; BOT, basal supported oral therapy; EQ-5D, EuroQol-5D;
QALY, quality-adjusted life years; SF-36, Short Form 36; T1D, type 1
diabetes mellitus; T2D, type 2 diabetes mellitus.
*Utility estimate used in the base case analysis.
impact on HRQoL they are often under-reported due to the
difficulty in defining/classifying events. This is an important
consideration for future studies because any difference in
the rate of NSHEs may influence health utility scores and
productivity [7,39].
Significant improvements in overall physical health and
reductions in body pain among patients with T2D [17,19,21]
receiving IDeg made substantial contributions to the between-
treatment difference in utility scores. These benefits may
have been derived from differences in the preparation of the
two insulins. Notably, localized injection-site pain has been
reported among patients receiving IGlar [40].
For reasons of consistency, the flexible dosing potential
of IDeg has not been explored in this meta-analysis, but it
may offer further benefits to health utility through increased
adherence and reduced anxiety over injection schedules. A
separate study is warranted to investigate whether flexible
dosing of basal insulin improves health utility compared with
fixed-time dosing.
A central assumption in meta-analyses such as the present
one is that a general treatment effect applies across the different
populations and conditions of the individual studies. We did
indeed find significant differences in baseline utility levels
between regions and between trials. However, we controlled
for these differences in the analyses and we did not find any
indications of a differential treatment effect by trial.
This analysis provides an estimated value for the difference
in health utility between IDeg and IGlar. Though modest, the
estimated difference between treatments appears real. When
preference-based measures are used in the process of allocating
healthcare resources, it is the difference in cost-effectiveness
(incremental cost per QALY) that is important, rather than the
change in QoL [41]. It should also be noted that the reduced
rate of hypoglycaemia in IDeg may provide further economic
advantages through decreased cost of testing strips, improved
productivity and a reduction in the number of admissions to
emergency departments [7,42].
There were some limitations to this analysis, specifically the
open-label design of the trials, which is often perceived as being
vulnerable to bias. With this in mind, the SF-36 questionnaire
was completed first at baseline, prior to randomisation, to
limit brand-specific bias. In addition, the duration of the trials
was sufficiently long that any emotions relating to starting or
changing insulin regimens should have diminished by the end
of the trial period. The fact that trial populations are subject
to exclusion criteria, such as severe recurrent hypoglycaemia
and diabetes-related complications, suggests that the patients
included in this meta-analysis are likely to have higher baseline
health utility scores than the mean for the general population
of patients with diabetes. ‘Real-world’ evidence is necessary to
confirm the results of these clinical trials.
The EQ-5D has attracted criticism for lacking a dimension
for energy/vitality [43]. Given that vitality was significantly
improved in IDeg SF-36 scores, but not captured by the
conversion algorithm, the differences in utility scores reported
here may be underestimated. Strengths of this study include
the randomized controlled trial context, the preplanned nature
of the analysis and the use of individual patient-level data.
In summary, the results of this preplanned meta-analysis
show that IDeg treatment improves HRQoL compared with
IGlar, at equivalent levels of glycaemic control. Future studies
should seek to investigate any potential relationship between
reduced rates of hypoglycaemia in patients treated with IDeg,
and improvements in HRQoL.
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